Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q1 EPS of ($0.46).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Braveheart Bio (BRVE) at Buy
- Guggenheim Downgrades Tenax Therapeutics (TENX) to Neutral
- High Tide plans three new Canna Cabana stores in Ontario and Saskatchewan
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
